Wuxi Biortus (“ortus” meaning sunrise in Latin) Biosciences Co. Ltd. was founded in 2009. The company is located in Jiangyin in close proximity to Shanghai. It is an innovation-driven contract research organization (CRO) committed to high-quality R&D services in support of drug discovery.
To help our clients achieve their drug discovery goals, we have established four world-class research platforms:
Through the years, our R&D team has developed a number of practical and innovative techniques. With our wide-range research capabilities and strong relevant expertise, we have delivered many projects to clients including international and domestic pharmaceuticals, biotechnology companies, and research institutions.
In Biortus, we utilize all major expression hosts, E.coli, yeast, insect and mammalian cells for our protein expression purposes. Since establishment, we have successfully delivered over 500 recombinant proteins, mostly enzymes and membrane proteins. The enzymes range from kinases, reductases, polymerases to epigenetic targets and others.
Besides conventional recombinant proteins, Biortus has protocol in place for customized protein modification such as Se-Met derivatisation, isotope labelling, biotinylation, PEG modification and more. Upon request, we can also deliver gram scale reagent grade antibodies for our clients in 6-8 weeks.
Upon customer request, Biortus routinely searches for the best expression conditions for a novel recombinant protein from the three major expression hosts (E. coli, Insect and mammalian). We offer a wide selection of plasmids and cells for achieving optimal expression.
With a total of 10 AKTA FPLC systems and a great selection (affinity, ion exchange, reverse phase, hydrophobic interaction, and size exclusion) of purification columns, Biortus Biology Department is well-equipped for purification of macromolecular biomolecules.
Compound screening against a drug target whether by high-throughput screening or fragment screening is a vital step in early stage drug discovery. Biortus has an extensive collection of plate readers (detecting UV/light absorbance, fluorescence, luminescence, and scintillation) that allows development of many kinds of biochemical assays including cell-based assays. Coupled with our automated liquid handling machines, we could perform various high-throughput screening (HTS) for our clients. Biortus currently holds two additional specialized screening technologies, Mobility Shift Assays (Caliper EZ Reader II, great for monitoring enzyme reactions) and Surface Plasmon Resonance (SPR, Biacore S200) for fragment screening.
Biortus has acquired SPR (Biacore S200) technology offering fragment screening services for clients. This medium-throughput screening technology allows sensitive detection of weakly binding fragments and provides the rate constant of binding (Kon and Koff). With our highly experienced assay development scientists and in-house fragment library consisting of around 3500 rule-of-3 compliant fragments, Biortus is ever ready to help you start your fragment-based drug discovery program.
Biortus offers two Rule-of-3 compliant fragment libraries dissolved in DMSO at 100mM in 96 and 384-well format. Aqueous solubility of all fragments was tested to be a minimum of 1mM. Biortus Fragment Library 1 has a total of 1159 compounds of which 137 overlaps with Biortus Fragment Library 2 (2500 fragment in total). Depending on the expected hit rate of the target, clients have a choice of a smaller or bigger fragment library and screening of both libraries with a total of 3522 unique compounds.
Capillary electrophoretic separation prior to fluorescence detection in a Caliper LabChip mobility shift assay offers improved assay reliability and extends assay applicability to mixed samples. The direct, quantifiable and real time monitoring of substrate and product level makes it particularly useful for enzyme assays. For example, the activity of a kinase could be measured by monitoring the formation of a phosphorylated fluorescently labelled peptide.
Structural Biology has always been a core strength of Biortus. Here, we employ modern technologies for structural studies: X-ray crystallography and Cryo-EM. We are not only able to provide protein structures for structure-based and fragment-based drug discovery, but also differentiate ourselves from other CROs by working on difficult structures like membrane proteins, large protein complexes, and epitope mapping.
Our Cryo-EM team consists of experts experienced in solving complex protein structures at atomic resolution. With in-house equipment and access to multiple Cryo-EM facilities, our team developed a number of practical and innovative techniques, and delivered many projects to international and domestic clients. Biortus offers milestone-based services, ranging from sample preparation (expression, separation and purification, negative staining etc.) to low resolution structure determination (~ 7-10A), to high resolution structure modeling (~ 3A). Customer can choose the best option that fits the stage of its project.
With our in-house Rigaku FR-E+ SuperBright Rotating Anode Coupled with R-axis IV++ Plate Area diffractometer, we could readily collect high-resolution data. To increase data collection throughput, Biortus has frequent access to the Shanghai Synchrotron Radiation Facility (SSRF), of which high-resolution data sets are collected within minutes, as well as other facilities such as Advanced Photon Source (APS) in Chicago, the European Synchrotron Radiation Facility (ESRF) in Grenoble, the Canadian Synchrotron Radiation Facility (CSRF), the Super Photon Ring – 8 GeV in Japan and more.
Biortus chemistry department is dedicated to the aspects of medicinal chemistry, custom synthesis and process development in the field of drug discovery and development. Our chemists are well equipped with modern instruments and have ample experiences in pharmaceutical R&D and synthetic organic chemistry. Within the 7000m2 of office/lab space, there are 8x100m2 laboratories, each has 14 fume hoods hosting up to 10 chemists, which could handle reaction scale from several milligrams to a kilogram. Furthermore, we have specialized facilities such as walk-in fume hoods, 100L reactors and likes in place for industrial scale compound synthesis (up to 20kg). Our mission is to drive client projects forward in a timely and cost-effective manner.
Wuxi Biortus Biosciences Co., Ltd. has not received any endorsements.